ACTIVATION DE LYMPHOCYTES T AUXILIAIRES/INDUCTEURS HUMAINS, LYMPHOCYTES T CYTOTOXIQUES/ SUPPRESSEURS, LYMPHOCYTES B ET CELLULES TUEUSES NATURELLES (NK) ET INDUCTION DE L'ACTIVITÉ DE CELLULES TUEUSES NATURELLES CONTRE DES CELLULES DE LEUCÉMIE MYÉLOÏDE CHRONIQUE K562 AYANT DE LA PECTINE DE CITRUS MODIFIÉE

• 收藏
• 分享

专利权人:

ECONUGENICS; INC.

发明人:

ELIAZ, ISAAC

申请号：

EP12789021

公开号：

EP2680704A4

申请日:

2012.02.28

申请国别(地区):

EP

年份:

2015

代理人:

摘要：

Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/